2025 年 6 月 10 日 星期二 每日大市点评 6 月 9 日，中美在伦敦开启第二轮经贸磋商，港股大盘高开高走。恒生指数全日上升 389 点或 1.6%，收报 24,181 点，为 今年 3 月 18 日以来收市新高，恒生指数下一个重要关口将是 3 月 19 日的高点(24,874 点)。恒生科指上升 2.8%，收报 5,433 点。大市成交金额有 2,458 多亿港元，但港股通净流入仅 7.2 亿港元，内资高追意愿不大，更多以趁机获利或仓位 轮动为主。盘面上，非银金融、生物医药、平台消费、软件或 AI 相关板块升幅比较突出，其他板块个股升跌各半。港交 所(388 HK)受惠于年内 PO 数目及成交增加而持续强势，股价上升 3.3%，创超过三年新高 "新消费"股古茗(1364 HK)、蜜雪集团(2097 HK)及布鲁可(325 HK)首天获纳入港股通，三只股份获资金大幅流入，但最 终表现分化，其中布鲁可大升 22.3%收报 193.3 港元，创上市新高，但古茗及蜜雪均冲高后回落，最终仅上升 4.3%及 5.4%，未能创出新高。这些股份短期或因纳入港股通而获得显著增量资金，但其估值已经不便宜。该类"新消费 ...

市场憧憬中美元首通电，港股大盘全周先跌后升，恒生指数全周上升 2.2%，收报 23,792 点。恒生科指全周上升 2.2%，收 报 5,286 点。恒指公司上周五季检生效，使大市成交金额增加至 2,356 亿港元，但全周日均成交也按周下跌 7.6%至 2,039 亿港元，显示大多投资者仍在观望中。港股通全周净流入 149 亿港元，风格继续偏好高分红。板块上，材料及医疗保健行 业分类指数上分别升大升 5.6%及 4.1%，前者受到黄金及铜有色股份带动，后者则受惠于市场对中国创新药 BD 交易的预 期。全球市场风险偏好上升有助于港股表现，但当前估值已大幅修复，AH 溢价指数偏低，整体大盘以偏震荡为主。由于 部分焦点板块升幅已较大，较易有获利了结的倾向，预计未来一周港股难有明确主线，更多以板块轮动为主。 中美元首上周通话，双方同意团队继续落实好日内瓦共识，尽快举行新一轮会谈。我们认为消息有助于纾缓中美双边紧 张气氛，减少不确定性，促进港股情绪进一步修复。不过，中美双方在关税税率、高端芯片的进口、市场改革、产业补 贴、芬太尼等多方面仍存在较多分歧，预计中美能够达成共识的进度较缓慢且反复。 上周个别年内升幅凌厉的"新消 ...

Core Viewpoint - Hansoh Pharmaceutical Group announced the approval of Amelot (Ametinib Mesylate Tablets) for a new indication, expanding its application to treat adult non-small cell lung cancer (NSCLC) patients with specific EGFR mutations [1][2] Group 1: Product Approval and Clinical Research - The new indication is for patients with stage II-III B NSCLC who have previously undergone surgical resection and may or may not receive adjuvant chemotherapy [1] - The approval is based on the ARTS (HS-10296-302) Phase III clinical study, which was presented at the 2025 American Association for Cancer Research (AACR) annual meeting [1] - The ARTS study demonstrated a significant improvement in disease-free survival (DFS) for patients receiving Amelot as adjuvant therapy, with a 2-year DFS rate of 90.2% [1] Group 2: Market Position and Expansion - Amelot, as China's first original third-generation EGFR-TKI, has been expanding its treatment areas since its launch five years ago [2] - The recent approval allows Amelot to cover early to mid-stage NSCLC (II-III stage), providing more treatment options for lung cancer patients in China [2]

Group 1 - Palin Bio received an administrative regulatory decision from Shanxi Securities Regulatory Commission due to internal control deficiencies and inaccurate information disclosure, leading to warnings for its management [1] - Maiwei Bio's chairman Liu Datao is under investigation for suspected short-term trading, which may affect investor confidence and the company's reputation despite claims of no impact on daily operations [2] - Gilead Sciences reached a settlement of $202 million with the U.S. government over kickback allegations, which could negatively impact investor confidence and the company's reputation if compliance issues are not addressed [3] Group 2 - Rongchang Bio's ADC drug, Vidisicimab, received approval from NMPA for treating HER2-positive advanced breast cancer, marking a significant market opportunity and potential revenue increase for the company [4] - Hansoh Pharma's innovative drug Amivantamab received NMPA approval for a new indication, expanding its market potential and likely boosting sales and investor interest [5]

Major Events - Jin'an Industrial (02292) received a privatization offer from its controlling shareholder at a premium of approximately 30%, with resumption of trading on May 12 [1] - Jingtai Holdings (02228) plans to acquire 90% of Shanghai Siwei Medical for 250 million yuan, aiming to create an AI-enabled remote electrocardiogram diagnosis platform [1] - China Investment and Financing (01226) is in contact with MCHKI to explore several potential corporate activities following unusual stock price movements [1] - Qiu Tai Technology (01478) reported camera module sales of 33.229 million units in April, an increase of 8.4% month-on-month but a decrease of 20.1% year-on-year [1] - Stone Pharmaceutical Group (01093) received approval for clinical trials of SYH2046 in the United States [1] - Fosun Pharma (02196) subsidiary Junji Health obtained FDA approval for drug clinical trials [1] - Rongchang Bio (09995) received approval for the marketing of Aidiqi® for treating HER2-positive advanced breast cancer with liver metastasis in China [1] - Livzon Pharmaceutical (01513) received approval for the marketing of injectable aripiprazole microspheres [1] - GAC Group (02238) reported April automobile production of 108,600 units, a year-on-year decline of 25.74% [2] - China Overseas Development (00688) reported contract property sales of approximately 20.164 billion yuan in April, a year-on-year decrease of 7.5% [2] Share Buybacks/Reductions - China Hongqiao (01378) repurchased 19.667 million shares for 273 million HKD on May 9 [1] - AIA Group (01299) repurchased 1.5 million shares for 92.1915 million HKD on May 9 [1] - Cathay Securities (02611) repurchased 1.6906 million A-shares for 29.3356 million yuan on May 9 [1] - Times Electric (03898) repurchased 610,300 shares for 19.7008 million HKD on May 9 [1] - East Asia Bank (00023) acquired 52.8 million shares from Sumitomo Mitsui Banking Corporation [1] - Shandong Molong (00568) saw shareholder Zhimo Holdings reduce its holdings by 28.81 million H-shares [1] Operating Performance - Longyuan Power (00916) achieved a power generation volume of 6.9064 million MWh in April, a year-on-year increase of 4.85% [2] - New天绿色能源 (00956) reported a power generation volume of 1.4778 million MWh in April, a year-on-year increase of 16.91% [2] - Jianye Real Estate (00832) achieved a total property contract sales amount of 2.71 billion yuan in the first four months, a year-on-year increase of 4.8% [2] - China Overseas Hongyang Group (00081) reported a cumulative contract sales amount of 9.556 billion yuan in the first four months, a year-on-year decrease of 14.1% [2] - Times China Holdings (01233) reported a cumulative contract sales amount of approximately 1.81 billion yuan in the first four months, a year-on-year decrease of 29.87% [2] - Agile Property Holdings (01813) reported a pre-sale amount of 509 million yuan in April, a year-on-year decrease of 47.5% [2] - Greenland Hong Kong (00337) reported contract sales of approximately 880 million yuan in the first four months, a year-on-year decrease of 69.3% [2]

Core Viewpoint - The 2025 CSCO Guidelines Conference has introduced the 2025 edition of the CSCO Guidelines for the Diagnosis and Treatment of Primary Non-Small Cell Lung Cancer (NSCLC), highlighting the inclusion of Hansoh Pharmaceutical's Amelot (Ametinib Mesylate Tablets) as the first Chinese original third-generation EGFR-TKI to receive a Class I recommendation for consolidation therapy in EGFR mutation-positive stage III unresectable NSCLC patients after chemoradiotherapy [1][2][3] Group 1 - The new recommendation is based on positive results from the POLESTAR study, a nationwide, multicenter, randomized, double-blind, controlled phase III clinical trial assessing the efficacy and safety of Amelot in consolidation therapy for stage III unresectable NSCLC patients with EGFR mutations after chemoradiotherapy [2] - The mid-term analysis of the POLESTAR study, presented at the 2024 World Lung Cancer Conference, showed a median progression-free survival (mPFS) of 30.4 months for the Amelot group, compared to 3.8 months for the placebo group, indicating an 8-fold improvement and an 85% reduction in the risk of disease progression or death [2] - The POLESTAR study exclusively included Chinese patients, demonstrating the significant efficacy of original EGFR-TKIs for domestic patients and providing high clinical relevance for China [2] Group 2 - NSCLC accounts for approximately 85% of all lung cancer cases in China, with nearly one-third being locally advanced (stage III) NSCLC, highlighting the urgent need for more precise and effective treatment options [2] - The rapid development of third-generation EGFR-TKIs represents a significant advancement in targeted therapy, offering more treatment choices to improve the diagnosis and treatment levels of stage III unresectable NSCLC and enhance patient prognosis [2] - The inclusion of Amelot as a Class I recommendation for consolidation therapy in this context confirms its application potential and is expected to guide the development of precision diagnosis and treatment for NSCLC in China, ultimately benefiting patients [3]